DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-774/S-003/S-004/S-005/S-007/S-008

Sanofi Aventis U.S., LLC
300 Somerset Corporate Blvd.
Bridgewater, NJ 08807

Attention: Qinghua (Sarah) Ji, M.D.
Assistant Director, Regulatory Development

Dear Dr. Ji:

Please refer to your supplemental new drug applications noted below submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Ambien CR (zolpidem tartrate) tablets.

Application	Submitted on:	Received on:	Provides for:
S-003	February 20, 2007	February 20, 2007	Efficacy Supplement for increase duration of use (6 months) of Ambien CR 12.5 mg (adults) and 6.25 mg (elderly)
S-004	March 7, 2007	March 8, 2007	"Changes Being Effected" Supplement; revisions to Warnings and Precautions section
S-005	April 17, 2007	April 18, 2007	"Changes Being Effected" Supplement; revisions to Warnings and Precautions section and Overdosage section
S-007	August 14, 2007	August 15, 2007	"Prior Approval" Supplement; Medication Guide
S-008	September 20, 2007	September 20, 2007	"Prior Approval" Supplement; Drug-Drug Interaction

We also acknowledge receipt of your amendments to these applications dated April 17, 2007, May 23, 2007, August 28, 2007 and September 20, 2007.

We have completed our review of supplemental new drug applications **S-003 and S-007**, and they are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling and medication guide text.

Content of Labeling

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at http://www.fda.gov/oc/datacouncil/spl.html that is identical to the enclosed labeling (text for the package insert, text for the Medication Guide). Upon receipt, we will transmit that version to the

National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "SPL for approved NDA 21-774/S-003."

Fulfillment of Pediatric Research Equity Act (PREA) Study Requirements

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application because there is evidence strongly suggesting that Ambien (zolpidem) would be ineffective or unsafe in all pediatric age groups. Our determination is based upon data submitted and reviewed as part of the pediatric studies for exclusivity submitted for your Ambien immediate-release product. That information has been described in the pediatric use section of labeling.

Promotional Materials

The Division of Drug Marketing, Advertising, and Communications (DDMAC) has reviewed the enclosed product labeling and has determined that it contains significant new risk information relating to your drug product. Therefore, we are hereby informing you that all promotional materials that include representations about Ambien CR should be revised to include the new risk information immediately. These revisions should include prominent disclosure of the important new information described in the WARNINGS and PRECAUTIONS sections that appear in the revised package labeling. If you have any questions about the promotion of your drug products, please contact DDMAC by facsimile at (301)796-9878 or at the address provided below.

In addition, please send one copy to the Division of Neurology Products and two copies of both the promotional materials and the proposed package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

Dear Healthcare Professional Letter

We note that, on March 14, 2007, you issued a Dear Health Care Professional Letter (DHCP) that informed healthcare professional about the risks of sleep-driving and anaphylaxis. If you have not yet done so, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

Supplemental Applications S-004, S-005 and S-008

We note that additional supplemental applications **(S-004, S-005 and S-008)**, submitted on March 8, 2007, April 17, 2007, and September 20, 2007 respectively, have been superseded by supplemental applications **S-003** and **S-007**. Therefore we will not review supplemental applications **S-004, S-005** and **S-008**, but they will be retained for our files.

Other

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Cathleen Michaloski, MPH, Regulatory Project Manager, at (301) 796-1123.

Sincerely,

{See appended electronic signature page}

Russell Katz, M.D.
Director
Division of Neurology
Office of New Drugs 1
Center for Drug Evaluation and Research

Enclosure: Package Insert (incl Medication Guide)

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Russell Katz

12/20/2007 03:50:15 PM